Entero Therapeutics (NASDAQ:GRDX) Posts Earnings Results

Entero Therapeutics (NASDAQ:GRDX) issued its quarterly earnings data on Friday. The company reported ($2.01) earnings per share (EPS) for the quarter, FiscalAI reports. The firm had revenue of $0.09 million during the quarter.

Entero Therapeutics Stock Performance

NASDAQ:GRDX opened at $3.57 on Friday. The firm has a market cap of $24.67 million, a PE ratio of -1.90 and a beta of 1.86. The business’s 50 day moving average price is $3.88. Entero Therapeutics has a 1-year low of $1.73 and a 1-year high of $6.93.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Entero Therapeutics stock. DRW Securities LLC acquired a new position in shares of Entero Therapeutics, Inc. (NASDAQ:GRDX) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 48,623 shares of the company’s stock, valued at approximately $227,000. DRW Securities LLC owned 1.45% of Entero Therapeutics at the end of the most recent reporting period. 12.30% of the stock is owned by institutional investors and hedge funds.

Entero Therapeutics Company Profile

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company’s pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.